Accueil   Diary - News   All news New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases

New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases

 

  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular vascularization, alone and in combination with anti-VEGF treatment
  • Anti-CD160 could be a good alternative for poor responders to anti-VEGF treatments

 

 

ELSALYS BIOTECH, a new player in immuno-oncology, announces the publication of two studies validating the potential of its first-in-class anti-CD160 antibodies for the treatment of neovascular diseases of the eye. The first study reveals that in patients, CD160 endothelial expression in retinal vessels is higher and correlates with a wide range of ocular neovascular diseases, while the second reports the safety of the antibody and demonstrates, in relevant animal models, its therapeutic benefit alone and in combination with anti-VEGF agents, the current standards of care for retinal vascular pathologies.

 

 

Read the full press release